Meiji Seika Pharma Co., Ltd
http://www.meiji-seika-pharma.co.jp/english/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Meiji Seika Pharma Co., Ltd
Japan’s Drug Distribution Crisis: Pharma Urges Govt To Reform Pricing System
The impact of drug shortages in Japan, including of essential products, is being considered as part of government-level discussions to consider the appropriateness of the current reimbursement pricing system. Amid rising production costs and wider global challenges, some experts in the industry are now asking for price increases.
Keeping Track: Rebyota, Rezlidhia Rev Up US FDA Approvals; New Sponsors Sought For Poziotinib, Brexafemme
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Deal Watch: GSK Gets Rights To Spero’s Phase III Antibiotic
GSK takes equity stake in Spero, and global rights to tebipenem except for certain Asian markets. Merck KGaA gets rights to Nerviano’s next-generation PARP inhibitor for cancer.
Sawai Focuses On New Products, Supply To 'Retain Trust' of Japan Generic Industry
Looking back at recent company decisions to shift product strategy, restructure its US Upsher-Smith business and acquire manufacturing sites from a former domestic competitor, Sawai's president shares the breadth of the Japanese firm’s vision.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Chemo-Sero Therapeutic Research Institute of Japan
- Meiji Holdings
- Meiji Seika Kaisha
- KM Biologics Co., Ltd.
- Kaketsuken
- Romeck Pharma, LLC
- Meiji Pharma USA Inc.